Dimensional Fund Advisors LP Has $408.56 Million Position in Zoetis Inc. $ZTS

Dimensional Fund Advisors LP lifted its stake in Zoetis Inc. (NYSE:ZTS) by 15.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,792,847 shares of the company’s stock after buying an additional 365,459 shares during the period. Dimensional Fund Advisors LP’s holdings in Zoetis were worth $408,557,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Norges Bank bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $809,491,000. Diamond Hill Capital Management Inc. bought a new stake in shares of Zoetis during the third quarter valued at approximately $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares in the last quarter. Corient Private Wealth LLC lifted its position in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares during the period. Finally, Impax Asset Management Group plc boosted its stake in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Piper Sandler restated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday. BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Finally, UBS Group set a $136.00 target price on Zoetis in a research report on Thursday, January 29th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Stock Performance

NYSE ZTS opened at $126.06 on Thursday. The firm has a market cap of $53.21 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 1.92 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a 50 day moving average of $126.22 and a 200-day moving average of $133.50.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.